Search

everythinglearnresearchcommunity

for

Search:↓

Skin problems like itching, dry skin, and hair loss are more common in hepatitis C patients after interferon treatment, but lichen planus is not linked to the infection.

Chronic kidney disease can cause skin problems that affect patient quality of life, and treating these conditions can improve outcomes.

Many COVID-19 patients have long-term symptoms, especially women, but certain medications may help reduce these symptoms.

Transplanted hair follicles can resist hair loss from an autoimmune condition better than natural hair.

Most patients with chronic kidney disease have skin problems, which get worse as the disease progresses, and dialysis doesn't greatly reduce these issues.

A hemodialysis patient's hair loss was caused by the drug tinzaparin but stopped after switching to a different drug.

The study found no link between anxiety, vitamin B12, folate, TSH, ferritin, zinc levels, and trichodynia in telogen alopecia patients.

A woman's chronic headaches and hair loss were cured by treating her syphilis.

A high-fat diet caused severe health problems in female macaques but was reversible with a normal diet, while male macaques reacted differently.

A woman's hair loss, resembling an autoimmune condition, improved after treatment, but requires ongoing checks due to potential serious associations.

People with advanced chronic kidney disease often have skin problems, which can be treated with various medications and procedures to improve their quality of life.

Some patients may experience temporary total hair loss from hepatitis C treatment with PEG-interferon and ribavirin.

Some patients treated with peginterferon and ribavirin for chronic hepatitis C had mild to moderate skin reactions, but treatment did not need to be stopped.

People with allergies or high eosinophil levels have a higher chance of severe hair loss from alopecia areata, and sudden hair loss can indicate chronic graft-versus-host disease.

Most Korean systemic lupus erythematosus patients experienced hair loss, often as non-scarring diffuse hair loss, with non-scarring patch alopecia also common.

ALA-PDT is effective and safe for chronic X-ray dermatitis, providing complete or partial remission.

Patients with chronic skin conditions on systemic treatments did not have worse COVID-19 outcomes and could resume their treatments after recovery.

Permanent hair loss after bone marrow transplant can be caused by chemotherapy or chronic graft-versus-host disease.

The document concludes that various skin conditions have specific treatments, ranging from antihistamines for urticaria to surgery and medication for tumors and chronic skin diseases.

Stem cell treatment improved hair density in female hair loss patient.

Many patients experienced hair loss after COVID-19, with women affected more, starting on average 49 days post-infection.

Mycophenolate mofetil may improve symptoms and stop hair loss in Lichen planopilaris, but more research is needed.

The document concludes that skin biopsies, genetic and environmental factors, and specific treatments are important in managing cutaneous lupus erythematosus.

Psychological factors like depression may be more important than zinc, folate, and vitamin B12 levels in causing scalp pain in people with hair loss.

A girl with no hair neglect developed plica neuropathica in the hospital, lost all her hair, but it grew back.

A man with Cronkhite-Canada syndrome had all 20 nails detach but improved with treatment.

Lupus affects the skin in various ways, and proper skin examination is crucial for diagnosis and treatment.

A cancer drug called nilotinib might cause hair loss due to inflammation around hair follicles.

The document provided instructions for completing a CME exam on diagnosing and managing hair loss.

The document concludes that different types of hair loss have specific treatments, and early diagnosis is crucial for preventing permanent hair loss.